News and Conferences

Page 1 of 16

  1. Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL

    We’re delighted to announce the strategic acquisition of OrganoTherapeutics SARL, a leader in patient-derived organoid technologies that advance the discovery and development of novel therapies for neurodegenerative/CNS disorders.

  2. IASP 2026 World Congress on Pain

    Yassine Darbaky, PhD, Global Pain SME, will attend the IASP 2026 World Congress on Pain in Bangkok, Thailand. Yassine Darbaky will present a poster entitled SPIDAR: Decision-Ready In Vivo Multi-Assay Platform for Analgesic Fingerprints and CNS Tolerability. Transpharmation will also exhibit at the conference.

  3. Animal Health, Nutrition & Technology Innovation (AHNTI) USA Summit 2026

    Shalini Kot, Associate Director, Business Development, and Joseph Araujo, Board Member and Co-Founder, will attend the Animal Health, Nutrition & Technology Innovation (AHNTI) USA Summit 2026 in Boston, Massachusetts, USA.

  4. Cumulus Neuroscience and Transpharmation Partner to Carry Objective EEG Measurement from Preclinical Research into First-in-Human Studies

    Transpharmation has partnered with Cumulus Neuroscience to help CNS drug developers move from animal models into first-in-human studies. The partnership lines up the quantitative EEG and cognitive endpoints in our preclinical models with those Cumulus’s NeuLogiq® Platform captures in the clinic. This gives sponsors one objective measure of brain function that follows a molecule across species.

  5. 39th ECNP Congress

    Małgorzata Domżalska, PhD, Senior Scientific Director, will attend the 39th ECNP Congress in Munich, Germany. Małgorzata Domżalska will present a poster entitled Rapid and Sustained Antidepressant-Like Effects of Hallucinogenic and Non-Hallucinogenic Serotonergic Compounds in a Chronic Social Defeat Model.

  6. Safety Pharmacology Society Annual Meeting 2026

    Briana Renda, PhD, Scientific Director and Head of Abuse Liability, and Shalini Kot, MSc, Associate Director of Business Development, will attend the Safety Pharmacology Society Annual Meeting 2026 in Montreal, Quebec, Canada.

  7. 9th Annual Neuropsychiatric Drug Development Summit

    Guy Higgins, PhD, Chief Behavioural Scientist, and Wendy Sauer, Business Development Manager, will attend the 9th Annual Neuropsychiatric Drug Development Summit in Boston, Massachusetts, USA. Guy Higgins will present Application of Operant Procedures to Investigate Novel (Non)Psychedelics and Treatments for ADHD, prepared with Parisa Moazen, PhD, Scientific Director and Head of Operant.

  8. PolLASA 2026

    Magdalena Borowiec-Pawlak, DVM, and Anna Przyborowska, PhD, will attend PolLASA 2026 in Warsaw, Poland, presenting two posters focused on laboratory mouse welfare and refinement strategies.

  9. BioJapan 2026

    Mark Duxon, PhD, Chief Executive Officer, Jolanta Golec, Business Development Manager, and Yurie Hayashi, PhD, Scientist, will attend BioJapan 2026 in Yokohama, Japan.

  10. 16th European Epilepsy Congress

    Daniel Hutcheson, PhD, Chief Scientific Officer, and Denvor Oorloff, Associate Director, Business Development, will attend the 16th European Epilepsy Congress in Athens, Greece. Daniel Hutcheson will present a poster entitled Behavioural Characterization of Interictal Comorbidities in the Corneal Kindling Model (Poster #P0215) on September 6, 2026.

Page 1 of 16

Want to see our latest study results?

Sign up for our newsletter.

Emails with our latest study results and news, from time to time. Unsubscribe anytime. See our Privacy Policy.

Newsletters

  • What's Next in CNS Drug Discovery? Five Studies Worth Exploring
  • Advancing Science Through In Vivo Refinement and Innovation - Examples from Abuse Liability and Impulsivity Screening
  • Building Confidence in Decision Making
  • Welcome to Reading, UK
  • The Next Leap in Translational Neuroscience
  • Expanding Scientific Possibility
  • 2025 Was A Year of Momentum: Science, People and Partners
  • 2025 Was A Year of Momentum: Science, People and Partners
  • Seven Posters, One Goal: Driving Neuroscience Forward
  • Advancing Preclinical Science for Next-Gen Therapies
  • New Capabilities Coming Online
  • Discover What's New at Transpharmation
  • Unlock the Microbiome: Transform Health with Transpharmation's Advanced Studies
  • Experimental Autoimmune Encephalomyelitis (EAE): Maximising The Therapeutic Efficacy of Fingolimod
  • Cross-Species Epilepsy Research: Revealing the Potential of the Zebrafish Model
  • Monoamine depletion to induce chronic allodynia and behavioural changes: a model of fibromyalgia
  • Take your R&D pipeline into the AI era with Moseq (Motion Sequencing), our new behavioural machine-learning assay!
  • Canine Microbiome
  • Oral Health: Not just for Humans
  • Novel Object Recognition: A Reliable Assay for Addressing Cognitive Impairments in Schizophrenia
  • Pre-pulse Inhibition: A Promising Screening Tool for Novel Compounds
  • Natural and induced models of osteoarthritis in Beagle dogs
  • Utilizing Rapid Screening Tests to Assess the Antidepressant Potential of Psychedelic Analogues
  • Long-term antidepressant effect of ketamine and psilocybin in the Chronic Social Defeat stress model
  • Diabetes and Metabolic Syndrome
  • Transpharmation's Animal Health Services
  • Longevity Research Goes to the Dogs
  • Transpharmation's Cutting-Edge Antiepileptic Drug Screening: A Global Solution for Advancing Epilepsy Research
  • PTZ-treated Zebrafish provide a high throughput platform for screening novel anti-epileptic drugs
  • Beyond Seizures: Epilepsy Comorbidities Explored in Mouse Kindling Studies
  • Novelty-suppressed feeding and novelty-induced hypophagia: exploring sex differences and response to diazepam in C57BL/6J mice.
  • Development & validation of intrathecal dosing in rats and mice
  • Transpharmation's Mouse-EEG capability reveals cross-species effects of novel antidepressants ketamine and psilocybin
  • Oral Health: Not just for Humans...
  • Accelerate Your Diabetes Drug Development with Transpharmation's Dog Diabetes Models
  • Introducing our new data analysis service for tremor-plate signals!
  • Introducing the Scn1a mutant mouse model of Dravet Syndrome at Transpharmation
  • New validated pre-clinical model to assess treatments for post-surgical pain
  • Experimental Autoimmune Encephalomyelitis; Modelling Multiple Sclerosis and Beyond
  • New Preclinical Models of Migraine for Assessment of Rescue and Preventive Analgesic Treatments
  • Do Your Compounds Exhibit Anti-Inflammatory Compounds
  • Profile your anti-inflammatory compounds in primary human immune cells
  • New EEG services from Transpharmation. Read on for results...
  • Accelerate your Drug Discovery Research. Proven results, fast and cost effective
  • Urgent Treatments Needed for Parkinson's Disease
  • Poor bioavailability, is the liver or intestine to blame?
  • Laser Doppler; new validated protocols revealed.
  • Epilepsy models leading the way. Read on for results.
  • Profiling anti-inflammatory drugs; from rodent to human
  • The Mismatch Negativity Challenge
  • Accelerate your drug discovery research. Proven science based results cost-effectively.
  • Anxiety. Three preclinical tests; data revealed...
  • Seven new posters, presented at SfN, now available to view.
  • Name change announcement! News from the CEO.
  • Chronic fatigue: different etiologies influence translational models
  • Seven new translational studies to share with you at this year's SfN event. Read on for poster titles and contact details.
  • Translational value increased with non-evoked pain measures.
  • Rapid access to PK non-rodent studies. Leading expertise.
  • Essential tremor research
  • Can a psychedelic experience be modelled in rats?
  • Gender Differences in Pain. New research revealed!
  • New data on the effect of single dose psilocybin!
  • From ketamine to psychedelics, join our webinar starting tomorrow!
  • Long term delayed effects of psychedelics in preclinical models. Trailblazing results revealed!
  • Accreditation awarded with flying colours
  • Breaking news! Merger announcement between Transpharmation and InterVivo Solutions.
  • Take a look! New posters, nine therapeutic areas available to view now.
  • Nine new compelling studies to be revealed at SfN21!
  • Can changes in EEG improve neuropathic pain treatments?
  • 40Hz ASSR: sounds that change our thoughts about schizophrenia
  • Clerkenwell Health and Transpharmation combine lab and human trials for psilocybin
  • Translational endpoints for preclinical pain - improving your chances.
  • Transpharmation aims for global standard. Let's talk about lab sustainability.
  • Targeting the unmet medical need in Parkinson's Disease - the fastest growing neurological disorder.
  • Psilocybin: the power of mental reorganisation
  • Expansion to world class premises
  • Multiple therapeutic indications
  • Focus on pain
  • Gene therapies for body and brain in Duchenne Muscular Dystrophy, progress moves forward.
  • Announcing Transpharmation Poland!